Lymphoma, Non-Hodgkin Clinical Trial
— CUPCAKEOfficial title:
Fitness Assessment in Young Adults Recovered From Lymphoma or Hodgkin's Disease
Verified date | November 2021 |
Source | University Hospital, Clermont-Ferrand |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Regular physical activity (PA) is associated with maintaining body composition, increased cardiorespiratory capacity, muscle mass and bone mineral density. In the event of a cancer, the development of physical capacities and metabolism may therefore be disturbed by cancer, these associated treatments (chemotherapy, radiotherapy and hematopoietic stem cell transplantation) but also undernutrition and the reduction in physical activity or even a sedentary lifestyle. Although the benefits of PA in oncology are now well identified for adult populations, studies are still rare in the population of children, adolescents and young adults, and the results are still difficult to generalize. As a result, there is no recommendation on the practice of physical activity in pediatric oncology or adolescents and young adults and the levels of physical activity of cured patients remain lower than those of the general population. Fitness is a marker of health in adults as well as in adolescents. Physical condition is a set of components such as cardiorespiratory capacity (transport and use of O2), body composition (distribution of bone, muscle and fat masses) and muscle function (strength, power, fatigue, energy metabolism) . The investigators hypothesize that, compared to young adults, recovered from lymphoma are expected to exhibit impaired physical condition, due to physical deconditioning.
Status | Completed |
Enrollment | 44 |
Est. completion date | December 6, 2022 |
Est. primary completion date | December 6, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 25 Years |
Eligibility | Inclusion Criteria: - Young adult male or female, aged 18 to 25 - giving free and informed consent - Hodgkin lymphoma or non-Hodgkin lymphoma in the healing stage - Cured (defined by an undetectable disease at the end of treatment) for at least one year and maximum 6 years of lymphoma or Hodgkin's disease Exclusion Criteria: - Legal incapable adults - People under judicial protection - Treatment with systemic glucocorticoids for more than a week, during the 30 days preceding the tests - Medical contraindication to the practice of physical exercise - Any pathologies (other than the history of lymphoma for the cases) likely to affect the metabolism or the muscle mass - Any treatment that may have an influence on the energy metabolism - Active infection - Pregnant, breastfeeding, or likely to be - Subject's refusal to participate |
Country | Name | City | State |
---|---|---|---|
France | CHU de Clermont-Ferrand | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | fat oxidation rate | maximum rate of lipid oxidation (in mg/ml) | day at 11:30 am during one day | |
Secondary | rest metabolism | energy expenditure at rest in kcal. | at 08:00 am in fasted condition during one day | |
Secondary | blood insulinemia | blood value of insulin in pmol/L | at 07:30 am in fasted condition during one day | |
Secondary | blood N-terminal pro-B natriuretic peptide | blood N-terminal pro-B natriuretic peptide level in g/L | at 07:30 am in fasted condition during one day | |
Secondary | blood troponin | blood troponin level in g/L | at 07:30 am in fasted condition during one day | |
Secondary | blood lipids | blood lipids level in g/L | at 07:30 am in fasted condition during one day | |
Secondary | blood glucose | blood glucose level in g/L | at 07:30 am in fasted condition during one day | |
Secondary | Body composition: fat | percentage of fat | at 07:30 am during one day | |
Secondary | Body composition: lean mass | percentage of lean mass | at 07:30 am during one day | |
Secondary | cardiac output | Systolic Ejection Volume in mL evaluated at rest and during submaximal exercise | at 11:30 am during one day | |
Secondary | peripheral quantitative computed tomography | Cross-sectional area of thigh muscles and intermuscular adipose tissue were assessed for muscle at 40% of the length between the greater trochanter and the mid-patella of the right leg | at 10:45 am during one day | |
Secondary | physical condition | 3 min step-test (number of ascent / descent step) | at 08:45 am during one day | |
Secondary | physical capacity | chair test (time in second held in position) | at 08:45 am during one day | |
Secondary | physical activity level | daily energy expenditure (in Kcal) | from day 2 to day 5 | |
Secondary | sedentary level | total sedentary time (in min) evaluated by accelerometer for 4 days | from day 2 to day 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03484702 -
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Completed |
NCT06190457 -
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
|
||
Completed |
NCT02369016 -
Phase III Copanlisib in Rituximab-refractory iNHL
|
Phase 3 | |
Recruiting |
NCT01676805 -
Tissue Collection for Studies of Lymph Cancer
|
||
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Completed |
NCT00534989 -
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
|
N/A | |
Terminated |
NCT00529503 -
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
|
Phase 2 | |
Withdrawn |
NCT00538096 -
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
|
Phase 1 | |
Completed |
NCT00156013 -
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00319332 -
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
|
Phase 3 | |
Completed |
NCT00141297 -
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT00322842 -
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
|
Phase 2 | |
Completed |
NCT02509039 -
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
|
Phase 1 | |
Completed |
NCT01573000 -
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
|
Phase 2 | |
Completed |
NCT00268203 -
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT03289182 -
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
|